Why Taysha’s Rett syndrome data could become a major gene therapy test case
Find out how Taysha’s TSHA-102 Rett syndrome update could shape gene therapy development, BLA planning and future disease-modifying care.
Pharma & Biotech
Pharma & Biotech
Regeneron’s cemdisiran enters FDA and EMA review for generalized myasthenia gravis
Find out how Regeneron’s cemdisiran review could reshape generalized myasthenia gravis care with potential quarterly subcutaneous dosing.
Pharma & Biotech
Could Praxis Precision Medicines’ Phase 3 ulixacaltamide data redefine the treatment pathway in essential tremor?
Praxis Precision Medicines’ positive Phase 3 ulixacaltamide data could reshape essential tremor treatment. Discover what this means for neurology and investors.